ARGENX SE (ARGX) Form 6-K — Oct 19, 2026
argenx announced that Phase 3 ALKIVIA results in autoimmune myositis will be presented as a late-breaking oral presentation at ACR Convergence 2026 on November 11. The study met its primary endpoint, with efgartigimod delivering a 15.4-point greater improvement in mean Total Improvement Score versus placebo at Week 52 (47.95 vs 32.56; p=0.0011) in the combined IMNM and dermatomyositis population. Improvements appeared as early as Week 4, were sustained through 52 weeks even with steroid tapering, and the safety profile was consistent with prior studies.
Key figures
- Presentation
- Late-breaking oral #LB24 at ACR Convergence 2026, November 11, 9:15-9:30 AM ET
- Us dm patients
- 40000
- Us imnm patients
- 20000
- Patients randomized
- 265
- Us myositis patients
- 100000
- Phase3 patients treated
- 175
- Primary endpoint result
- 15.4-point greater improvement in mean Total Improvement Score (TIS) vs placebo at Week 52 (47.95 vs 32.56; p=0.0011)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.